StockMacro
Menu

Tarsus Pharmaceuticals

$73.01 +19% in 6 monthsMarket cap $3.6B

TARS on XNAS, Health Care, Tarsus Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue up 64% but the stock is down 5.2% in 12 months while 12% of shares are sold short.

  • GoodTwelve-month revenue up 86% to $682.2M
  • BadNet loss of $702.2M over 12 months on $682.2M of revenue

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
370
Website
tarsusrx.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 22 Feb 2027 (an estimate: a year ago it reported on 23 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $194.6M, net loss $668.3M.
Quarter to 31 Dec 2021: revenue –, net income -$14.9MQuarter to 31 Mar 2022: revenue $539K, net income -$20.2MQuarter to 31 Mar 2022: revenue $539K, net income -$20.2MQuarter to 30 Jun 2022: revenue $15.3M, net income -$5.7MQuarter to 30 Jun 2022: revenue $15.3M, net income -$5.7MQuarter to 30 Sep 2022: revenue $0, net income -$22.5MQuarter to 30 Sep 2022: revenue $0, net income -$22.5MQuarter to 31 Dec 2022: revenue $10.0M, net income -$13.6MQuarter to 31 Dec 2022: revenue $10.0M, net income -$13.6MQuarter to 31 Mar 2023: revenue $2.5M, net income -$23.4MQuarter to 31 Mar 2023: revenue $2.5M, net income -$23.4MQuarter to 30 Jun 2023: revenue $0, net income -$31.4MQuarter to 30 Jun 2023: revenue $0, net income -$31.4MQuarter to 30 Sep 2023: revenue $1.9M, net income -$39.1MQuarter to 30 Sep 2023: revenue $1.9M, net income -$39.1MQuarter to 31 Dec 2023: revenue –, net income -$41.9MQuarter to 31 Mar 2024: revenue $27.6M, net income -$35.7MQuarter to 31 Mar 2024: revenue $27.6M, net income -$35.7MQuarter to 30 Jun 2024: revenue $40.8M, net income -$33.3MQuarter to 30 Jun 2024: revenue $40.8M, net income -$33.3MQuarter to 30 Sep 2024: revenue $48.1M, net income -$23.4MQuarter to 30 Sep 2024: revenue $48.1M, net income -$23.4MQuarter to 31 Dec 2024: revenue $66.4M, net income -$23.1MQuarter to 31 Dec 2024: revenue $66.4M, net income -$23.1MQuarter to 31 Mar 2025: revenue $78.3M, net income -$25.1MQuarter to 31 Mar 2025: revenue $78.3M, net income -$25.1MQuarter to 30 Jun 2025: revenue $102.7M, net income -$20.3MQuarter to 30 Jun 2025: revenue $102.7M, net income -$20.3MQuarter to 30 Sep 2025: revenue $118.7M, net income -$12.6MQuarter to 30 Sep 2025: revenue $118.7M, net income -$12.6MQuarter to 31 Dec 2025: revenue $151.7M, net income -$8.4MQuarter to 31 Dec 2025: revenue $151.7M, net income -$8.4MQuarter to 31 Mar 2026: revenue $162.1M, net income -$7.0MQuarter to 31 Mar 2026: revenue $162.1M, net income -$7.0MQuarter to 30 Jun 2026: revenue $173.9M, net income -$18.6MQuarter to 30 Jun 2026: revenue $173.9M, net income -$18.6MQuarter to 30 Sep 2026: revenue $194.6M, net income -$668.3MQuarter to 30 Sep 2026: revenue $194.6M, net income -$668.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $668.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$194.6M-$668.3M
30 Jun 2026$173.9M-$18.6M
31 Mar 2026$162.1M-$7.0M
31 Dec 2025$151.7M-$8.4M
30 Sep 2025$118.7M-$12.6M
30 Jun 2025$102.7M-$20.3M
31 Mar 2025$78.3M-$25.1M
31 Dec 2024$66.4M-$23.1M
30 Sep 2024$48.1M-$23.4M
30 Jun 2024$40.8M-$33.3M
31 Mar 2024$27.6M-$35.7M
31 Dec 2023–-$41.9M
30 Sep 2023$1.9M-$39.1M
30 Jun 2023$0-$31.4M
31 Mar 2023$2.5M-$23.4M
31 Dec 2022$10.0M-$13.6M
30 Sep 2022$0-$22.5M
30 Jun 2022$15.3M-$5.7M
31 Mar 2022$539K-$20.2M
31 Dec 2021–-$14.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $682.2M $366.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +86% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$702.2M -$81.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$15.18 -$2.01
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -102% -23.9% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -103% -22.2% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -320% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $32.4M -$57.5M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $309.6M $401.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $72.9M $72.3M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$236.7M (net cash) -$329.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.70 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.11
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 4.9 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 34.6 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Tarsus PharmaceuticalsTARS (this company) $3.6Bloss5.3+86%-103%
Relay TherapeuticsRLAY $3.6Bloss–––
CRISPR Therapeutics AGCRSP $3.8Bloss151-34%–
Iovance BiotherapeuticsIOVA $3.2Bloss8.4+51%-58.2%
Denali TherapeuticsDNLI $3.0Bloss–––
VericelVCEL $2.9B88.19.1+25%10.3%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$6.0M

bought $0, sold $6.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+0.4%

255 13F filers vs 254

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

52.3M shares held by 13F filers (30 Sep 2026) of 49.3M outstanding (29 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

6.1M shares sold short (30 Oct 2026) of 49.3M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.9

6.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+5.8%

5.7M shares sold short in the report before, 6.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

61%

61% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

23

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+64%

$194.6M vs $118.7M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-36%

$1.2M vs $1.9M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$200K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.0×

6 articles in the last 7 days; its usual week has 2.

Price $73.01 on 20 Nov 2026, -5.2% over 12 months (12-month range $56.11 to $90.78)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $20.8M in the last 12 months (the 12 months before: -$6.8M).
Revenue per quarter. Revenue $194.6M in the latest quarter, +64% on a year earlier.
Capital spending per quarter. Capital spending $1.2M in the latest quarter, -36% on a year earlier.
Institutional holders (13F filers). 255 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.
Lobbying spend. Lobbying spend: $200K published in the last 12 months, +33% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Sep 20268-K and other filingsCompleted an acquisition or asset sale
13 Jul 20268-K and other filingsDirector or officer change
13 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.8M vs usual 796K (2026-03-31); 9.9x the same period a year earlier
24 Feb 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 6.4M vs usual 482K (2025-12-31); 88.3x the same period a year earlier
18 Feb 20268-K and other filingsDirector or officer change
18 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 66.4M vs usual 11.5M (2024-12-31); 5.1x the same period a year earlier
4 Apr 2025Lobbying filingnew lobbying registration (FORBES-TATE)
4 Apr 2025Sharp changeFirst lobbying registration: first lobbying registration: TARSUS PHARMACEUTICALS: new lobbying registration (FORBES-TATE)
17 Jan 20258-K and other filingsDirector or officer change
19 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 48.1M vs usual 6.2M (2024-09-30); 25.7x the same period a year earlier
5 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 40.8M vs usual 2.2M (2024-06-30)
14 May 2024Sharp changeQuarterly revenue change: quarterly revenue change, 27.6M vs usual 2.2M (2024-03-31); 11.0x the same period a year earlier
18 Jan 20248-K and other filingsDirector or officer change
18 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jan 2024Sharp changeShort interest spike: short interest spike, 4.9M vs usual 1.3M (2023-12-15); 5.6x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 4.5M vs usual 1.1M (2023-11-30); 3.6x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 4.5M vs usual 1.1M (2023-11-15); 3.5x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 4.2M vs usual 1.1M (2023-10-31); 2.8x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 4.0M vs usual 1.1M (2023-10-13); 2.7x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 5.0M vs usual 1.1M (2023-09-29); 3.3x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 4.4M vs usual 1.1M (2023-09-15); 3.5x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 4.5M vs usual 1.1M (2023-08-31); 3.6x the same period a year earlier
29 Aug 2023Sharp changeShort interest spike: short interest spike, 4.5M vs usual 1.1M (2023-08-15); 3.6x the same period a year earlier
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 23 vs usual 8.50 (2023-06-30); 1.0x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.1M (2023-07-31); 3.0x the same period a year earlier
1 Aug 2023Sharp changeShort interest spike: short interest spike, 2.3M vs usual 1.1M (2023-07-14); 1.7x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 2.2M vs usual 1.1M (2023-06-30); 1.8x the same period a year earlier
24 Apr 20238-K and other filingsDirector or officer change
24 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Dec 20228-K and other filingsDirector or officer change
15 Nov 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 493K (2022-10-31); 4.6x the same period a year earlier
1 Nov 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 421K (2022-10-14); 4.5x the same period a year earlier
18 Oct 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 396K (2022-09-30); 4.5x the same period a year earlier
12 Oct 20228-K and other filingsDirector or officer change
12 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Sep 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 387K (2022-09-15); 3.8x the same period a year earlier
13 Sep 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 369K (2022-08-31); 4.1x the same period a year earlier
30 Aug 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 341K (2022-08-15); 4.0x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 331K (2022-07-29); 4.0x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 330K (2022-07-15); 4.0x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 1.2M vs usual 329K (2022-06-30); 3.8x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 637K vs usual 328K (2022-06-15); 2.3x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 570K vs usual 328K (2022-04-29); 1.5x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 588K vs usual 328K (2022-04-14); 1.5x the same period a year earlier
12 Apr 2022Sharp changeShort interest spike: short interest spike, 548K vs usual 328K (2022-03-31); 1.3x the same period a year earlier
4 Jan 20228-K and other filingsDirector or officer change
4 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$288K published
Month from 1 May 2022: -$5.6M published
Month from 1 Aug 2022: -$214K published
Month from 1 Sep 2022: -$58K published
Month from 1 Oct 2022: -$358K published
Month from 1 Nov 2022: -$500K published
Month from 1 Dec 2022: -$412K published
Month from 1 Jan 2023: -$358K published
Month from 1 Feb 2023: -$334K published
Month from 1 Mar 2023: -$498K published
Month from 1 Apr 2023: -$214K published
Month from 1 May 2023: -$431K published
Month from 1 Jun 2023: -$469K published
Month from 1 Jul 2023: -$2.3M published
Month from 1 Aug 2023: $22K published
Month from 1 Sep 2023: -$138K published
Month from 1 Oct 2023: -$135K published
Month from 1 Nov 2023: -$147K published
Month from 1 Dec 2023: -$1.3M published
Month from 1 Mar 2024: -$882K published
Month from 1 Jun 2024: -$287K published
Month from 1 Aug 2024: -$913K published
Month from 1 Mar 2025: -$3.3M published
Month from 1 Jun 2025: -$1.4M published
Month from 1 Aug 2025: -$300K published
Month from 1 Sep 2025: -$1.9M published
Month from 1 Dec 2025: -$3.1M published
Month from 1 Jan 2026: -$1.3M published
Month from 1 Mar 2026: -$7.9M published
Month from 1 Jun 2026: -$2.5M published
Month from 1 Sep 2026: -$5.2M published
Month from 1 Nov 2026: -$803K published
Revenue per quarter
Quarter ended 31 Dec 2020: $0; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $539K, -98% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $15.3M, -31% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $0, -100% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $10.0M; public on 18 Mar 2023
Quarter ended 31 Mar 2023: $2.5M, +364% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2023: $1.9M; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $27.6M, +1005% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $40.8M; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $48.1M, +2472% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $66.4M; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $78.3M, +184% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $102.7M, +152% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $118.7M, +147% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $151.7M, +128% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $162.1M, +107% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $173.9M, +69% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $194.6M, +64% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $274K; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $161K, -8.0% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $122K, +662% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $96K, -21% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $127K, -54% on a year earlier; public on 18 Mar 2023
Quarter ended 31 Mar 2023: $340K, +111% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $787K, +545% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $375K, +291% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $174K, -49% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $1.0M, +32% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $282K, -25% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $72K; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $590K, +239% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $1.0M, -3.7% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $1.9M, +577% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $6.4M, +8731% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $5.8M, +886% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $4.1M, +306% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.2M, -36% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 39; public on 14 Feb 2022
31 Mar 2022 report: 48; public on 16 May 2022
30 Jun 2022 report: 70; public on 15 Aug 2022
30 Sep 2022 report: 69; public on 14 Nov 2022
31 Dec 2022 report: 66; public on 14 Feb 2023
31 Mar 2023 report: 74; public on 15 May 2023
30 Jun 2023 report: 85; public on 14 Aug 2023
30 Sep 2023 report: 101; public on 14 Nov 2023
31 Dec 2023 report: 109; public on 14 Feb 2024
31 Mar 2024 report: 153; public on 15 May 2024
30 Jun 2024 report: 143; public on 14 Aug 2024
30 Sep 2024 report: 159; public on 14 Nov 2024
31 Dec 2024 report: 187; public on 14 Feb 2025
31 Mar 2025 report: 188; public on 15 May 2025
30 Jun 2025 report: 198; public on 14 Aug 2025
30 Sep 2025 report: 210; public on 14 Nov 2025
31 Dec 2025 report: 239; public on 17 Feb 2026
31 Mar 2026 report: 248; public on 15 May 2026
30 Jun 2026 report: 254; public on 14 Aug 2026
30 Sep 2026 report: 255; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2025: $50K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $50K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $44.2M (30 Sep 2026), 2.9× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $20.8M in the last 12 months (the 12 months before: -$6.8M).
  • Revenue per quarter: Revenue $194.6M in the latest quarter, +64% on a year earlier.
  • Capital spending per quarter: Capital spending $1.2M in the latest quarter, -36% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 7 sales, $6.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
17 Nov 2026Bobak R. AzamianPresident/CEO and Board ChairSellplanned in advance (10b5-1)10,000$80.31$803KForm 4
17 Sep 2026William J Link PhdDirectorSellplanned in advance (10b5-1); after exercising options12,500$78.38$980KForm 4
9 Sep 2026Bobak R. AzamianPresident/CEO and Board ChairSellplanned in advance (10b5-1)10,000$90.56$906KForm 4
9 Sep 2026Elizabeth Yeu LinChief Medical OfficerSellplanned in advance (10b5-1)13,953$87.50$1.2MForm 4
9 Sep 2026Seshadri NeervannanChief Operating OfficerSellplanned in advance (10b5-1)4,564$85.00$388KForm 4
3 Sep 2026Elizabeth Yeu LinChief Medical OfficerSellplanned in advance (10b5-1)11,578$77.56$898KForm 4
3 Sep 2026Bobak R. AzamianPresident/CEO and Board ChairSellplanned in advance (10b5-1)10,000$80.06$801KForm 4
22 Jun 2026Bobak R. AzamianPresident/CEO and Board ChairSellplanned in advance (10b5-1)10,000$61.55$615KForm 4

255 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 42 opened a position, 42 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.3.9M7.84%$303.9M+10K+0.3%
Deep Track Capital, LP3.8M7.72%$299.3M+140K+3.8%
RTW Investments, LP3.5M7.07%$273.9M+127K+3.8%
FMR LLC (Fidelity)3.3M6.64%$250.4M+2.6M+386%
Janus Henderson Group Ltd.2.9M5.84%$226.4M
Paradigm Biocapital Advisors LP2.3M4.67%$180.9M-474K-17%
Vestal Point Capital, LP2.0M4.12%$159.9M+984K+94%
Tang Capital Management LLC1.9M3.89%$150.7M+349K+22%
Vanguard Capital Management LLC1.9M3.81%$147.7M+86K+4.8%
Morgan Stanley1.7M3.47%$134.5M-116K-6.4%

Company events

All 26 company events

In 12 months: 3 major agreements, 2 director or officer changes, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Sep 2026Completed an acquisition or asset sale8-K
6 Aug 2026Signed a major agreementSame filing: sold shares privately8-K
6 Aug 2026Signed a major agreementSame filing: sold shares privately8-K
13 Jul 2026Director or officer change8-K
8 Jul 2026Signed a major agreementSame filing: sold shares privately8-K
18 Feb 2026Director or officer change8-K
13 Mar 2025Signed a major agreement8-K
17 Jan 2025Director or officer change8-K

23 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 30%, Legal, policy & compliance 22%, Finance & accounting 9%, Program & project management 9%.

PostedJobLocation
20 Nov 2026Head of Government AffairsLegal, policy & complianceWashington, District of Columbia, United States
17 Nov 2026Territory Leader - ScrantonSales & business developmentScranton, Pennsylvania, United States
16 Nov 2026Associate Director, R&D Quality AssuranceFinance & accountingUnited States - Remote
5 Nov 2026Sr Director, FP&A (R&D)Finance & accountingIrvine, California, United States
29 Oct 2026Director, Program Team LeadOperations & administrationIrvine, California, United States
28 Oct 2026VP, Market AccessMarketing & communicationsIrvine, California, United States
27 Oct 2026Territory Leader - Rhode IslandSales & business developmentProvidence, Rhode Island, United States
22 Oct 2026Director, HR Business PartnerPeople & recruitingIrvine, California, United States

Reported lobbying spend: $50K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
20 Feb 2025NewForbes-Tatefor Tarsus PharmaceuticalsEducation and advocacy related to life science products and pipeline.Health issuesFiling

The 5 newest of 116 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

1 May 2025confirmed

Confirmed across sources Filings + Financials and Lobbying

Tarsus Pharmaceuticals (TARS): registered for federal lobbying for the first time in our data (Forbes-Tate), while it reported revenue of $66.4M for the quarter ended 31 Dec 2024, 5.1× the same quarter last year. Two unrelated kinds of activity within 27 days.

  • Lobbying: First lobbying registration, became public on 4 Apr 2025
  • Financials: Quarterly revenue change, became public on 1 May 2025
2022-12-31: $10.0M2023-03-31: $2.5M2023-06-30: $02023-09-30: $1.9M2023-12-31: $13.1M2024-03-31: $27.6M2024-06-30: $40.8M2024-09-30: $48.1M2024-12-31: $66.4M
The quarter ended 31 Dec 2024 against the 8 quarters before it. this quarterearliernormal: $11.5M
See the evidence (2 changes)

Lobbying: First lobbying registration became public on 4 Apr 2025

Tarsus Pharmaceuticals registered for federal lobbying for the first time in our data (Forbes-Tate).

Source coverage starts
7 Oct 2008
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Financials: Quarterly revenue change became public on 1 May 2025

Tarsus Pharmaceuticals reported revenue of $66.4M for the quarter ended 31 Dec 2024, 5.1× the same quarter last year.

This period
$66.4M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$11.5M
Typical spread (median absolute deviation)
$10.6M
How far from its usual level
+3.5
Same quarter last year
$13.1M
History used
1,736 days
2022-12-31: $10.0M2023-03-31: $2.5M2023-06-30: $02023-09-30: $1.9M2023-12-31: $13.1M2024-03-31: $27.6M2024-06-30: $40.8M2024-09-30: $48.1M2024-12-31: $66.4M
the quarter ended 31 Dec 20248 earlier quartersnormal: $11.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 Aug 2023confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Tarsus Pharmaceuticals (TARS): saw 23 13F filers open a new position in the quarter ended 30 Jun 2023, 1.0× the same quarter last year, while it had 4.5M shares sold short in the 30 Nov 2023 report, 3.6× the same report last year. Two unrelated kinds of activity within 168 days.

  • Short interest and volume: Short interest spike, became public on 13 Jul 2023
  • Short interest and volume: Short interest spike, became public on 26 Jul 2023
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
  • Short interest and volume: Short interest spike, became public on 10 Aug 2023
  • Short interest and volume: Short interest spike, became public on 25 Aug 2023
  • Short interest and volume: Short interest spike, became public on 13 Sep 2023
  • Short interest and volume: Short interest spike, became public on 27 Sep 2023
  • Short interest and volume: Short interest spike, became public on 12 Oct 2023
  • Short interest and volume: Short interest spike, became public on 25 Oct 2023
  • Short interest and volume: Short interest spike, became public on 10 Nov 2023
  • Short interest and volume: Short interest spike, became public on 28 Nov 2023
  • Short interest and volume: Short interest spike, became public on 12 Dec 2023
  • Short interest and volume: Short interest spike, became public on 28 Dec 2023
2021-06-30: 112021-09-30: 42021-12-31: 12022-03-31: 62022-06-30: 232022-09-30: 82022-12-31: 102023-03-31: 92023-06-30: 23
The quarter ended 30 Jun 2023 against the 8 quarters before it. this quarterearliernormal: 8.5
See the evidence (13 changes)

Short interest and volume: Short interest spike became public on 13 Jul 2023

Tarsus Pharmaceuticals had 2.2M shares sold short in the 30 Jun 2023 report, 1.8× the same report last year.

This period
2.2M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
144K
How far from its usual level
+5.2
Same report last year
1.2M
History used
973 days
2022-06-30: 1.2M2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M
the 30 Jun 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jul 2023

Tarsus Pharmaceuticals had 2.3M shares sold short in the 14 Jul 2023 report, 1.7× the same report last year.

This period
2.3M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
157K
How far from its usual level
+5.0
Same report last year
1.3M
History used
987 days
2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M
the 14 Jul 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

Tarsus Pharmaceuticals saw 23 13F filers open a new position in the quarter ended 30 Jun 2023, 1.0× the same quarter last year.

This period
23 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
8.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.9
Same quarter last year
23
History used
911 days
2021-06-30: 112021-09-30: 42021-12-31: 12022-03-31: 62022-06-30: 232022-09-30: 82022-12-31: 102023-03-31: 92023-06-30: 23
the quarter ended 30 Jun 20238 earlier quartersnormal: 8.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Aug 2023

Tarsus Pharmaceuticals had 3.8M shares sold short in the 31 Jul 2023 report, 3.0× the same report last year.

This period
3.8M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
157K
How far from its usual level
+11.5
Same report last year
1.3M
History used
1,004 days
2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M
the 31 Jul 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Aug 2023

Tarsus Pharmaceuticals had 4.5M shares sold short in the 15 Aug 2023 report, 3.6× the same report last year.

This period
4.5M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
169K
How far from its usual level
+13.3
Same report last year
1.3M
History used
1,019 days
2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M
the 15 Aug 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Sep 2023

Tarsus Pharmaceuticals had 4.5M shares sold short in the 31 Aug 2023 report, 3.6× the same report last year.

This period
4.5M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
174K
How far from its usual level
+13.1
Same report last year
1.3M
History used
1,035 days
2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M
the 31 Aug 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Sep 2023

Tarsus Pharmaceuticals had 4.4M shares sold short in the 15 Sep 2023 report, 3.5× the same report last year.

This period
4.4M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
199K
How far from its usual level
+11.0
Same report last year
1.3M
History used
1,050 days
2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M
the 15 Sep 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Oct 2023

Tarsus Pharmaceuticals had 5.0M shares sold short in the 29 Sep 2023 report, 3.3× the same report last year.

This period
5.0M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
242K
How far from its usual level
+10.7
Same report last year
1.5M
History used
1,064 days
2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M
the 29 Sep 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Oct 2023

Tarsus Pharmaceuticals had 4.0M shares sold short in the 13 Oct 2023 report, 2.7× the same report last year.

This period
4.0M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
242K
How far from its usual level
+8.0
Same report last year
1.5M
History used
1,078 days
2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M
the 13 Oct 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Nov 2023

Tarsus Pharmaceuticals had 4.2M shares sold short in the 31 Oct 2023 report, 2.8× the same report last year.

This period
4.2M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
242K
How far from its usual level
+8.5
Same report last year
1.5M
History used
1,096 days
2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M
the 31 Oct 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Nov 2023

Tarsus Pharmaceuticals had 4.5M shares sold short in the 15 Nov 2023 report, 3.5× the same report last year.

This period
4.5M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
242K
How far from its usual level
+9.3
Same report last year
1.3M
History used
1,111 days
2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M
the 15 Nov 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Dec 2023

Tarsus Pharmaceuticals had 4.5M shares sold short in the 30 Nov 2023 report, 3.6× the same report last year.

This period
4.5M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
271K
How far from its usual level
+8.3
Same report last year
1.2M
History used
1,126 days
2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M2023-11-30: 4.5M
the 30 Nov 2023 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Dec 2023

Tarsus Pharmaceuticals had 4.9M shares sold short in the 15 Dec 2023 report, 5.6× the same report last year.

This period
4.9M (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
445K
How far from its usual level
+5.5
Same report last year
874K
History used
1,141 days
2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M2023-11-30: 4.5M2023-12-15: 4.9M
the 15 Dec 2023 report24 earlier reportsnormal: 1.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Sep 2026Filings record

    Completed an acquisition or asset sale

  2. 13 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 13 Jul 2026Filings record

    Director or officer change

  4. 7 May 2026Financials change

    spent $5.8M on capital projects in the quarter ended 31 Mar 2026, 9.9× the same quarter last year.

    Same quarter last year: $590K; its normal quarter is $796K.

    See the evidence
    This period
    $5.8M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $796K
    Typical spread (median absolute deviation)
    $568K
    How far from its usual level
    +5.0
    Same quarter last year
    $590K
    History used
    2,282 days
    2024-03-31: $174K2024-06-30: $1.0M2024-09-30: $282K2024-12-31: $72K2025-03-31: $590K2025-06-30: $1.0M2025-09-30: $1.9M2025-12-31: $6.4M2026-03-31: $5.8M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $796K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  5. 24 Feb 2026Financials change

    spent $6.4M on capital projects in the quarter ended 31 Dec 2025, 88× the same quarter last year.

    Same quarter last year: $72K; its normal quarter is $482K.

    See the evidence
    This period
    $6.4M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $482K
    Typical spread (median absolute deviation)
    $360K
    How far from its usual level
    +5.9
    Same quarter last year
    $72K
    History used
    2,192 days
    2023-09-30: $375K2024-03-31: $174K2024-06-30: $1.0M2024-09-30: $282K2024-12-31: $72K2025-03-31: $590K2025-06-30: $1.0M2025-09-30: $1.9M2025-12-31: $6.4M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $482K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 18 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 18 Feb 2026Filings record

    Director or officer change

  8. 1 May 2025several at once

    registered for federal lobbying for the first time in our data (Forbes-Tate), while it reported revenue of $66.4M for the quarter ended 31 Dec 2024, 5.1× the same quarter last year. Two unrelated kinds of activity within 27 days.

    See the evidence (2 changes)

    Lobbying: First lobbying registration became public on 4 Apr 2025

    Tarsus Pharmaceuticals registered for federal lobbying for the first time in our data (Forbes-Tate).

    Source coverage starts
    7 Oct 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

    Financials: Quarterly revenue change became public on 1 May 2025

    Tarsus Pharmaceuticals reported revenue of $66.4M for the quarter ended 31 Dec 2024, 5.1× the same quarter last year.

    This period
    $66.4M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $11.5M
    Typical spread (median absolute deviation)
    $10.6M
    How far from its usual level
    +3.5
    Same quarter last year
    $13.1M
    History used
    1,736 days
    2022-12-31: $10.0M2023-03-31: $2.5M2023-06-30: $02023-09-30: $1.9M2023-12-31: $13.1M2024-03-31: $27.6M2024-06-30: $40.8M2024-09-30: $48.1M2024-12-31: $66.4M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $11.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  9. 1 May 2025Financials change

    reported revenue of $66.4M for the quarter ended 31 Dec 2024, 5.1× the same quarter last year.

    Same quarter last year: $13.1M; its normal quarter is $11.5M.

    See the evidence
    This period
    $66.4M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $11.5M
    Typical spread (median absolute deviation)
    $10.6M
    How far from its usual level
    +3.5
    Same quarter last year
    $13.1M
    History used
    1,736 days
    2022-12-31: $10.0M2023-03-31: $2.5M2023-06-30: $02023-09-30: $1.9M2023-12-31: $13.1M2024-03-31: $27.6M2024-06-30: $40.8M2024-09-30: $48.1M2024-12-31: $66.4M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $11.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  10. 4 Apr 2025Lobbying change

    registered for federal lobbying for the first time in our data (Forbes-Tate).

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  11. 4 Apr 2025Lobbying record

    TARSUS PHARMACEUTICALS: new lobbying registration (FORBES-TATE) (dated 20 Feb 2025)

  12. 17 Jan 2025Filings record

    Director or officer change

  13. 19 Nov 2024Financials change

    reported revenue of $48.1M for the quarter ended 30 Sep 2024, 26× the same quarter last year.

    Same quarter last year: $1.9M; its normal quarter is $6.2M.

    See the evidence
    This period
    $48.1M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $6.2M
    Typical spread (median absolute deviation)
    $6.2M
    How far from its usual level
    +4.5
    Same quarter last year
    $1.9M
    History used
    1,644 days
    2022-06-30: $15.3M2022-09-30: $02022-12-31: $10.0M2023-03-31: $2.5M2023-06-30: $02023-09-30: $1.9M2024-03-31: $27.6M2024-06-30: $40.8M2024-09-30: $48.1M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $6.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  14. 5 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 5 Nov 2024Filings record

    Director or officer change

  16. 13 Aug 2024Financials change

    reported revenue of $40.8M for the quarter ended 30 Jun 2024, against none in the same quarter last year.

    See the evidence
    This period
    $40.8M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $2.2M
    Typical spread (median absolute deviation)
    $2.2M
    How far from its usual level
    +11.9
    Same quarter last year
    $0
    History used
    1,552 days
    2022-03-31: $539K2022-06-30: $15.3M2022-09-30: $02022-12-31: $10.0M2023-03-31: $2.5M2023-06-30: $02023-09-30: $1.9M2024-03-31: $27.6M2024-06-30: $40.8M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $2.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 14 May 2024Financials change

    reported revenue of $27.6M for the quarter ended 31 Mar 2024, 11× the same quarter last year.

    Same quarter last year: $2.5M; its normal quarter is $2.2M.

    See the evidence
    This period
    $27.6M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $2.2M
    Typical spread (median absolute deviation)
    $1.9M
    How far from its usual level
    +9.0
    Same quarter last year
    $2.5M
    History used
    1,461 days
    2021-06-30: $22.0M2021-09-30: $1.2M2022-03-31: $539K2022-06-30: $15.3M2022-09-30: $02022-12-31: $10.0M2023-03-31: $2.5M2023-09-30: $1.9M2024-03-31: $27.6M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $2.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 18 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 18 Jan 2024Filings record

    Director or officer change

  20. 28 Dec 2023Short interest and volume change

    had 4.9M shares sold short in the 15 Dec 2023 report, 5.6× the same report last year.

    Same report last year: 874K; its normal report is 1.3M.

    See the evidence
    This period
    4.9M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    445K
    How far from its usual level
    +5.5
    Same report last year
    874K
    History used
    1,141 days
    2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M2023-11-30: 4.5M2023-12-15: 4.9M
    the 15 Dec 2023 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 20 Dec 2023Insiders record

    Goldberg Andrew D. (director) bought 1,000 shares of TARS ($18,960) (dated 19 Dec 2023)

  22. 12 Dec 2023Short interest and volume change

    had 4.5M shares sold short in the 30 Nov 2023 report, 3.6× the same report last year.

    Same report last year: 1.2M; its normal report is 1.1M.

    See the evidence
    This period
    4.5M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    271K
    How far from its usual level
    +8.3
    Same report last year
    1.2M
    History used
    1,126 days
    2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M2023-11-30: 4.5M
    the 30 Nov 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 28 Nov 2023Short interest and volume change

    had 4.5M shares sold short in the 15 Nov 2023 report, 3.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    4.5M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +9.3
    Same report last year
    1.3M
    History used
    1,111 days
    2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M
    the 15 Nov 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 10 Nov 2023Short interest and volume change

    had 4.2M shares sold short in the 31 Oct 2023 report, 2.8× the same report last year.

    Same report last year: 1.5M; its normal report is 1.1M.

    See the evidence
    This period
    4.2M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +8.5
    Same report last year
    1.5M
    History used
    1,096 days
    2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M
    the 31 Oct 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 25 Oct 2023Short interest and volume change

    had 4.0M shares sold short in the 13 Oct 2023 report, 2.7× the same report last year.

    Same report last year: 1.5M; its normal report is 1.1M.

    See the evidence
    This period
    4.0M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +8.0
    Same report last year
    1.5M
    History used
    1,078 days
    2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M
    the 13 Oct 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 12 Oct 2023Short interest and volume change

    had 5.0M shares sold short in the 29 Sep 2023 report, 3.3× the same report last year.

    Same report last year: 1.5M; its normal report is 1.1M.

    See the evidence
    This period
    5.0M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +10.7
    Same report last year
    1.5M
    History used
    1,064 days
    2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 27 Sep 2023Short interest and volume change

    had 4.4M shares sold short in the 15 Sep 2023 report, 3.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    4.4M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    199K
    How far from its usual level
    +11.0
    Same report last year
    1.3M
    History used
    1,050 days
    2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M
    the 15 Sep 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 13 Sep 2023Short interest and volume change

    had 4.5M shares sold short in the 31 Aug 2023 report, 3.6× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    4.5M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    174K
    How far from its usual level
    +13.1
    Same report last year
    1.3M
    History used
    1,035 days
    2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M
    the 31 Aug 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 25 Aug 2023Short interest and volume change

    had 4.5M shares sold short in the 15 Aug 2023 report, 3.6× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    4.5M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    169K
    How far from its usual level
    +13.3
    Same report last year
    1.3M
    History used
    1,019 days
    2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M
    the 15 Aug 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 18 Aug 2023Insiders record

    Lin Elizabeth Yeu (director) bought 9,506 shares of TARS ($159,701) (dated 17 Aug 2023)

  31. 15 Aug 2023several at once

    saw 23 13F filers open a new position in the quarter ended 30 Jun 2023, 1.0× the same quarter last year, while it had 4.5M shares sold short in the 30 Nov 2023 report, 3.6× the same report last year. Two unrelated kinds of activity within 168 days.

    See the evidence (13 changes)

    Short interest and volume: Short interest spike became public on 13 Jul 2023

    Tarsus Pharmaceuticals had 2.2M shares sold short in the 30 Jun 2023 report, 1.8× the same report last year.

    This period
    2.2M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    144K
    How far from its usual level
    +5.2
    Same report last year
    1.2M
    History used
    973 days
    2022-06-30: 1.2M2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M
    the 30 Jun 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jul 2023

    Tarsus Pharmaceuticals had 2.3M shares sold short in the 14 Jul 2023 report, 1.7× the same report last year.

    This period
    2.3M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    157K
    How far from its usual level
    +5.0
    Same report last year
    1.3M
    History used
    987 days
    2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M
    the 14 Jul 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

    Tarsus Pharmaceuticals saw 23 13F filers open a new position in the quarter ended 30 Jun 2023, 1.0× the same quarter last year.

    This period
    23 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +3.9
    Same quarter last year
    23
    History used
    911 days
    2021-06-30: 112021-09-30: 42021-12-31: 12022-03-31: 62022-06-30: 232022-09-30: 82022-12-31: 102023-03-31: 92023-06-30: 23
    the quarter ended 30 Jun 20238 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 10 Aug 2023

    Tarsus Pharmaceuticals had 3.8M shares sold short in the 31 Jul 2023 report, 3.0× the same report last year.

    This period
    3.8M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    157K
    How far from its usual level
    +11.5
    Same report last year
    1.3M
    History used
    1,004 days
    2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M
    the 31 Jul 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Aug 2023

    Tarsus Pharmaceuticals had 4.5M shares sold short in the 15 Aug 2023 report, 3.6× the same report last year.

    This period
    4.5M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    169K
    How far from its usual level
    +13.3
    Same report last year
    1.3M
    History used
    1,019 days
    2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M
    the 15 Aug 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Sep 2023

    Tarsus Pharmaceuticals had 4.5M shares sold short in the 31 Aug 2023 report, 3.6× the same report last year.

    This period
    4.5M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    174K
    How far from its usual level
    +13.1
    Same report last year
    1.3M
    History used
    1,035 days
    2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M
    the 31 Aug 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Sep 2023

    Tarsus Pharmaceuticals had 4.4M shares sold short in the 15 Sep 2023 report, 3.5× the same report last year.

    This period
    4.4M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    199K
    How far from its usual level
    +11.0
    Same report last year
    1.3M
    History used
    1,050 days
    2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M
    the 15 Sep 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Oct 2023

    Tarsus Pharmaceuticals had 5.0M shares sold short in the 29 Sep 2023 report, 3.3× the same report last year.

    This period
    5.0M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +10.7
    Same report last year
    1.5M
    History used
    1,064 days
    2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Oct 2023

    Tarsus Pharmaceuticals had 4.0M shares sold short in the 13 Oct 2023 report, 2.7× the same report last year.

    This period
    4.0M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +8.0
    Same report last year
    1.5M
    History used
    1,078 days
    2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M
    the 13 Oct 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Nov 2023

    Tarsus Pharmaceuticals had 4.2M shares sold short in the 31 Oct 2023 report, 2.8× the same report last year.

    This period
    4.2M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +8.5
    Same report last year
    1.5M
    History used
    1,096 days
    2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M
    the 31 Oct 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Nov 2023

    Tarsus Pharmaceuticals had 4.5M shares sold short in the 15 Nov 2023 report, 3.5× the same report last year.

    This period
    4.5M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    242K
    How far from its usual level
    +9.3
    Same report last year
    1.3M
    History used
    1,111 days
    2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M
    the 15 Nov 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Dec 2023

    Tarsus Pharmaceuticals had 4.5M shares sold short in the 30 Nov 2023 report, 3.6× the same report last year.

    This period
    4.5M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    271K
    How far from its usual level
    +8.3
    Same report last year
    1.2M
    History used
    1,126 days
    2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M2023-11-30: 4.5M
    the 30 Nov 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Dec 2023

    Tarsus Pharmaceuticals had 4.9M shares sold short in the 15 Dec 2023 report, 5.6× the same report last year.

    This period
    4.9M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    445K
    How far from its usual level
    +5.5
    Same report last year
    874K
    History used
    1,141 days
    2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M2023-08-15: 4.5M2023-08-31: 4.5M2023-09-15: 4.4M2023-09-29: 5.0M2023-10-13: 4.0M2023-10-31: 4.2M2023-11-15: 4.5M2023-11-30: 4.5M2023-12-15: 4.9M
    the 15 Dec 2023 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  32. 14 Aug 2023Institutional holdings change

    saw 23 13F filers open a new position in the quarter ended 30 Jun 2023, 1.0× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 8.5.

    See the evidence
    This period
    23 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +3.9
    Same quarter last year
    23
    History used
    911 days
    2021-06-30: 112021-09-30: 42021-12-31: 12022-03-31: 62022-06-30: 232022-09-30: 82022-12-31: 102023-03-31: 92023-06-30: 23
    the quarter ended 30 Jun 20238 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  33. 10 Aug 2023Short interest and volume change

    had 3.8M shares sold short in the 31 Jul 2023 report, 3.0× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    3.8M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    157K
    How far from its usual level
    +11.5
    Same report last year
    1.3M
    History used
    1,004 days
    2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M2023-07-31: 3.8M
    the 31 Jul 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 26 Jul 2023Short interest and volume change

    had 2.3M shares sold short in the 14 Jul 2023 report, 1.7× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    2.3M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    157K
    How far from its usual level
    +5.0
    Same report last year
    1.3M
    History used
    987 days
    2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M2023-07-14: 2.3M
    the 14 Jul 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 13 Jul 2023Short interest and volume change

    had 2.2M shares sold short in the 30 Jun 2023 report, 1.8× the same report last year.

    Same report last year: 1.2M; its normal report is 1.1M.

    See the evidence
    This period
    2.2M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    144K
    How far from its usual level
    +5.2
    Same report last year
    1.2M
    History used
    973 days
    2022-06-30: 1.2M2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M2022-11-15: 1.3M2022-11-30: 1.2M2022-12-15: 874K2022-12-30: 1.0M2023-01-13: 1.0M2023-01-31: 969K2023-02-15: 986K2023-02-28: 997K2023-03-15: 1.0M2023-03-31: 992K2023-04-14: 959K2023-04-28: 961K2023-05-15: 852K2023-05-31: 910K2023-06-15: 1.6M2023-06-30: 2.2M
    the 30 Jun 2023 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 24 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 24 Apr 2023Filings record

    Director or officer change

  38. 7 Dec 2022Filings record

    Director or officer change

  39. 10 Nov 2022Short interest and volume change

    had 1.5M shares sold short in the 31 Oct 2022 report, 4.6× the same report last year.

    Same report last year: 323K; its normal report is 493K.

    See the evidence
    This period
    1.5M (the 31 Oct 2022 report)
    Normal report (median of 24 earlier)
    493K
    Typical spread (median absolute deviation)
    168K
    How far from its usual level
    +4.0
    Same report last year
    323K
    History used
    731 days
    2021-10-15: 331K2021-10-29: 323K2021-11-15: 313K2021-11-30: 317K2021-12-15: 325K2022-01-14: 323K2022-01-31: 330K2022-02-15: 351K2022-02-28: 386K2022-03-15: 405K2022-03-31: 548K2022-04-14: 588K2022-04-29: 570K2022-05-13: 387K2022-05-31: 437K2022-06-15: 637K2022-06-30: 1.2M2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M2022-10-31: 1.5M
    the 31 Oct 2022 report24 earlier reportsnormal: 493K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 26 Oct 2022Short interest and volume change

    had 1.5M shares sold short in the 14 Oct 2022 report, 4.5× the same report last year.

    Same report last year: 331K; its normal report is 421K.

    See the evidence
    This period
    1.5M (the 14 Oct 2022 report)
    Normal report (median of 24 earlier)
    421K
    Typical spread (median absolute deviation)
    106K
    How far from its usual level
    +6.9
    Same report last year
    331K
    History used
    714 days
    2021-09-30: 329K2021-10-15: 331K2021-10-29: 323K2021-11-15: 313K2021-11-30: 317K2021-12-15: 325K2022-01-14: 323K2022-01-31: 330K2022-02-15: 351K2022-02-28: 386K2022-03-15: 405K2022-03-31: 548K2022-04-14: 588K2022-04-29: 570K2022-05-13: 387K2022-05-31: 437K2022-06-15: 637K2022-06-30: 1.2M2022-07-15: 1.3M2022-07-29: 1.3M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 1.3M2022-09-30: 1.5M2022-10-14: 1.5M
    the 14 Oct 2022 report24 earlier reportsnormal: 421K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 68 entries; narrow the window or the kind of data to see older ones.

Not listed: 227 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001819790
Ticker
TARS
Domain
tarsusrx.com
Hq location
CA|IRVINE|92618 (1 unverified)
Lobbying client
tarsus pharmaceuticals
Name
Tarsus Pharmaceuticals, Inc.
Uei
YJBRXANG28R5
  • Federal lobbying disclosures (LDA)1 record, 21 data points20 Feb 2025 to 30 Sep 2026
  • SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)92 records25 Sep 2020 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)471 data points31 Dec 2017 to 29 Oct 2026
  • SEC Form 4 insider transactions157 records, 360 data points20 Oct 2020 to 17 Nov 2026
  • FINRA short interest (twice monthly)431 data points30 Oct 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3064 data points16 Oct 2020 to 20 Nov 2026